Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,919.00p on 27-10-2026 at 15:07:07
Change 4.00p 0.21%
Buy 1,919.50p
Sell 1,918.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 0.00 at 1,919.00p
Day's Volume: 1,237,050
Last Close: 1,915.00p
Open: 1,907.00p
ISIN: GB00BN7SWP63
Day's Range 1,902.50p - 1,925.50p
52wk Range: 1,664.50p - 2,282.00p
Market Capitalisation: £76.89b
VWAP: 1,915.01714p
Shares in Issue: 4.01b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 0 1,919.00p SI Trade
 15:06:48 - 27-Oct-26
Unknown* 0 1,919.00p SI Trade
 15:06:39 - 27-Oct-26
Unknown* 0 1,919.00p SI Trade
 15:06:39 - 27-Oct-26
Sell* 140 1,919.00p Automatic Execution
 15:06:17 - 27-Oct-26
Sell* 786 1,918.6628p Ordinary
 15:06:04 - 27-Oct-26
Unknown* 0 1,919.00p SI Trade
 15:05:45 - 27-Oct-26
Unknown* 0 1,919.00p SI Trade
 15:05:06 - 27-Oct-26
Sell* 145 1,918.00p Automatic Execution
 15:04:50 - 27-Oct-26
Sell* 340 1,918.00p Automatic Execution
 15:04:48 - 27-Oct-26
Sell* 143 1,918.00p Automatic Execution
 15:04:48 - 27-Oct-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Oct 2026 (Tue) 1,907.00 1,925.50 1,902.50 1,915.00 1,237,050
26th Oct 2026 (Mon) 1,903.00 1,921.50 1,898.00 1,915.00 3,085,590
23rd Oct 2026 (Fri) 1,911.50 1,911.50 1,881.00 1,894.00 5,516,426
22nd Oct 2026 (Thu) 1,875.00 1,917.00 1,863.00 1,914.00 4,466,031
21st Oct 2026 (Wed) 1,863.50 1,884.00 1,856.50 1,868.00 11,052,161
20th Oct 2026 (Tue) 1,870.00 1,879.50 1,855.00 1,868.50 5,286,220
19th Oct 2026 (Mon) 1,871.00 1,871.00 1,851.00 1,855.00 4,924,273
16th Oct 2026 (Fri) 1,843.00 1,870.00 1,842.50 1,862.50 12,806,361
15th Oct 2026 (Thu) 1,823.50 1,876.50 1,812.00 1,868.50 12,523,051
14th Oct 2026 (Wed) 1,740.00 1,816.00 1,740.00 1,816.00 7,626,757
13th Oct 2026 (Tue) 1,797.00 1,806.50 1,753.00 1,753.00 6,612,895
12th Oct 2026 (Mon) 1,755.00 1,771.00 1,751.00 1,771.00 3,351,693
9th Oct 2026 (Fri) 1,752.00 1,771.50 1,748.50 1,750.00 6,930,730
8th Oct 2026 (Thu) 1,773.00 1,773.00 1,735.50 1,735.50 16,330,339
7th Oct 2026 (Wed) 1,754.50 1,791.00 1,747.00 1,790.50 5,172,175
6th Oct 2026 (Tue) 1,769.50 1,786.50 1,740.50 1,765.50 5,018,567
5th Oct 2026 (Mon) 1,786.50 1,789.50 1,755.00 1,759.00 3,779,090
2nd Oct 2026 (Fri) 1,781.00 1,802.00 1,770.00 1,779.50 5,629,788
1st Oct 2026 (Thu) 1,810.50 1,830.50 1,790.50 1,795.00 8,592,563
30th Sep 2026 (Wed) 1,864.50 1,873.50 1,824.50 1,832.00 9,778,649
29th Sep 2026 (Tue) 1,866.50 1,917.00 1,852.00 1,856.00 8,485,936
28th Sep 2026 (Mon) 1,863.00 1,872.00 1,841.00 1,860.00 4,381,276
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
26th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
26th Oct 2026 3:30 pm RNS Ris-Rez positive Ph 3 osteosarcoma data in China
26th Oct 2026 7:05 am RNS Jemperli data show 76% complete response rate
26th Oct 2026 7:00 am RNS Positive Mo-Rez Phase Ib data in ovarian cancer
21st Oct 2026 7:00 am RNS US FDA approves Hibsago for chronic hepatitis B
19th Oct 2026 5:21 pm RNS Jemperli approved in MSI-H/dMMR rectal cancer
19th Oct 2026 7:00 am RNS Ris-Rez positive early data in lung cancer
15th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
14th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
13th Oct 2026 3:30 pm RNS Director/PDMR Shareholding
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK gets positive results in drug trials for rectal and ovarian cancer

26th Oct 2026 09:19

(Alliance News) - GSK PLC has announced positive results from tests of its drug candidates for rectal and ovarian cancer. Read More

LONDON BRIEFING: Computacenter lifts outlook, Plus500 upbeat

26th Oct 2026 07:58

(Alliance News) - Computacenter raises its full-year profit outlook after strong third-quarter trading, while Plus500 forecast annual revenue and earnings ahead of market expectations. GSK has reported positive clinical trial results for two cancer treatments. Read More

GSK hails five-year ViiV Healthcare data on HIV treatment Cabenuva

21st Oct 2026 16:22

(Alliance News) - GSK PLC on Wednesday noted five-year data for ViiV Healthcare's HIV treatment Cabenuva, which the lead study author found "highly encouraging". Read More

UK earnings, trading statements calendar - next 7 days

21st Oct 2026 14:15

Read More

GSK wins US approval for hepatitis B drug as Hutchmed deal closes

21st Oct 2026 08:48

(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,679.91
Change-87.42

Login to your account

Forgot Password?

Not Registered